Annual Accounts Payable
$4.95 M
-$1.27 M-20.40%
December 31, 2023
Summary
- As of February 8, 2025, BCLI annual accounts payable is $4.95 million, with the most recent change of -$1.27 million (-20.40%) on December 31, 2023.
- During the last 3 years, BCLI annual accounts payable has fallen by -$2.36 million (-32.29%).
- BCLI annual accounts payable is now -67.81% below its all-time high of $15.39 million, reached on December 31, 2019.
Performance
BCLI Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$4.60 M
-$737.00 K-13.80%
September 30, 2024
Summary
- As of February 8, 2025, BCLI quarterly accounts payable is $4.60 million, with the most recent change of -$737.00 thousand (-13.80%) on September 30, 2024.
- Over the past year, BCLI quarterly accounts payable has dropped by -$737.00 thousand (-13.80%).
- BCLI quarterly accounts payable is now -70.09% below its all-time high of $15.39 million, reached on December 31, 2019.
Performance
BCLI Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
BCLI Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -20.4% | -13.8% |
| 3 y3 years | -32.3% | -13.8% |
| 5 y5 years | -4.2% | -13.8% |
BCLI Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -20.4% | +3.8% | -48.1% | +17.2% |
| 5 y | 5-year | -67.8% | +3.8% | -70.1% | +23.6% |
| alltime | all time | -67.8% | +2829.6% | -70.1% | >+9999.0% |
Brainstorm Cell Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $4.60 M(-13.8%) |
| Jun 2024 | - | $5.34 M(+13.9%) |
| Mar 2024 | - | $4.69 M(-5.3%) |
| Dec 2023 | $4.95 M(-20.4%) | $4.95 M(+26.2%) |
| Sep 2023 | - | $3.93 M(-37.2%) |
| Jun 2023 | - | $6.25 M(-29.5%) |
| Mar 2023 | - | $8.86 M(+42.4%) |
| Dec 2022 | $6.22 M(+30.4%) | $6.22 M(-16.2%) |
| Sep 2022 | - | $7.43 M(+17.5%) |
| Jun 2022 | - | $6.32 M(+11.5%) |
| Mar 2022 | - | $5.67 M(+18.8%) |
| Dec 2021 | $4.77 M(-34.8%) | $4.77 M(+28.2%) |
| Sep 2021 | - | $3.72 M(-13.6%) |
| Jun 2021 | - | $4.31 M(+4.0%) |
| Mar 2021 | - | $4.14 M(-43.4%) |
| Dec 2020 | $7.32 M(-52.5%) | $7.32 M(+70.3%) |
| Sep 2020 | - | $4.30 M(-23.2%) |
| Jun 2020 | - | $5.59 M(-2.6%) |
| Mar 2020 | - | $5.74 M(-62.7%) |
| Dec 2019 | $15.39 M(+197.7%) | $15.39 M(+54.2%) |
| Sep 2019 | - | $9.98 M(+4.8%) |
| Jun 2019 | - | $9.52 M(+66.4%) |
| Mar 2019 | - | $5.72 M(+10.7%) |
| Dec 2018 | $5.17 M(+146.1%) | $5.17 M(+59.9%) |
| Sep 2018 | - | $3.23 M(-32.5%) |
| Jun 2018 | - | $4.79 M(+21.8%) |
| Mar 2018 | - | $3.94 M(+87.3%) |
| Dec 2017 | $2.10 M(+195.1%) | $2.10 M(+206.3%) |
| Sep 2017 | - | $686.00 K(+14.9%) |
| Jun 2017 | - | $597.00 K(-14.6%) |
| Mar 2017 | - | $699.00 K(-1.8%) |
| Dec 2016 | $712.00 K(-51.0%) | $712.00 K(+15.0%) |
| Sep 2016 | - | $619.00 K(-1.7%) |
| Jun 2016 | - | $630.00 K(+11.1%) |
| Mar 2016 | - | $567.00 K(-61.0%) |
| Dec 2015 | $1.45 M(-17.8%) | $1.45 M(+174.0%) |
| Sep 2015 | - | $530.00 K(-48.1%) |
| Jun 2015 | - | $1.02 M(-11.6%) |
| Mar 2015 | - | $1.16 M(-34.6%) |
| Dec 2014 | $1.77 M(+288.1%) | $1.77 M(+11.8%) |
| Sep 2014 | - | $1.58 M(+53.7%) |
| Jun 2014 | - | $1.03 M(+79.2%) |
| Mar 2014 | - | $573.00 K(+25.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | $455.00 K(-17.4%) | $455.00 K(-32.7%) |
| Sep 2013 | - | $676.00 K(+13.8%) |
| Jun 2013 | - | $594.00 K(+46.7%) |
| Mar 2013 | - | $405.00 K(-26.5%) |
| Dec 2012 | $551.00 K(+43.1%) | $551.00 K(+106.4%) |
| Sep 2012 | - | $267.00 K(-59.5%) |
| Jun 2012 | - | $660.00 K(+46.3%) |
| Mar 2012 | - | $451.00 K(+17.1%) |
| Dec 2011 | $385.00 K(+25.4%) | $385.00 K(+52.2%) |
| Sep 2011 | - | $253.00 K(-62.8%) |
| Jun 2011 | - | $681.00 K(+69.8%) |
| Mar 2011 | - | $401.00 K(+30.6%) |
| Dec 2010 | $307.00 K(-48.8%) | $307.00 K(-31.2%) |
| Sep 2010 | - | $446.00 K(-21.2%) |
| Jun 2010 | - | $566.00 K(+5.0%) |
| Mar 2010 | - | $539.00 K(-10.2%) |
| Dec 2009 | $600.00 K(-19.4%) | $600.00 K(-22.8%) |
| Sep 2009 | - | $777.00 K(-4.0%) |
| Jun 2009 | - | $809.00 K(+5.9%) |
| Mar 2009 | - | $764.00 K(+2.7%) |
| Dec 2008 | $744.00 K(-29.1%) | $744.00 K(+0.9%) |
| Sep 2008 | - | $737.00 K(+3.9%) |
| Jun 2008 | - | $709.00 K(-12.7%) |
| Mar 2008 | - | $812.00 K(-22.6%) |
| Dec 2007 | $1.05 M(+20.0%) | $1.05 M(-31.2%) |
| Sep 2007 | - | $1.52 M(-14.9%) |
| Jun 2007 | - | $1.79 M(+11.7%) |
| Mar 2007 | - | $1.60 M(+65.7%) |
| Dec 2006 | $874.00 K(+53.0%) | - |
| Sep 2006 | - | $968.70 K(+35.0%) |
| Jun 2006 | - | $717.80 K(+25.7%) |
| Mar 2006 | - | $571.10 K(-21.6%) |
| Mar 2006 | $571.10 K(+237.7%) | - |
| Dec 2005 | - | $728.80 K(+24.3%) |
| Sep 2005 | - | $586.10 K(+36.9%) |
| Jun 2005 | - | $428.00 K(+153.1%) |
| Mar 2005 | $169.10 K | $169.10 K(+56.3%) |
| Dec 2004 | - | $108.20 K(+2064.0%) |
| Sep 2004 | - | $5000.00(+525.0%) |
| Sep 2003 | - | $800.00(-20.0%) |
| Jun 2003 | - | $1000.00(+66.7%) |
| Dec 2002 | - | $600.00(-92.9%) |
| Sep 2002 | - | $8400.00(+663.6%) |
| Jun 2002 | - | $1100.00 |
FAQ
- What is Brainstorm Cell Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual accounts payable year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly accounts payable year-on-year change?
What is Brainstorm Cell Therapeutics annual accounts payable?
The current annual accounts payable of BCLI is $4.95 M
What is the all time high annual accounts payable for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual accounts payable is $15.39 M
What is Brainstorm Cell Therapeutics annual accounts payable year-on-year change?
Over the past year, BCLI annual accounts payable has changed by -$1.27 M (-20.40%)
What is Brainstorm Cell Therapeutics quarterly accounts payable?
The current quarterly accounts payable of BCLI is $4.60 M
What is the all time high quarterly accounts payable for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly accounts payable is $15.39 M
What is Brainstorm Cell Therapeutics quarterly accounts payable year-on-year change?
Over the past year, BCLI quarterly accounts payable has changed by -$737.00 K (-13.80%)